GUFICBIO

Gufic BioSciences Share Price

₹445.10 -1.65 (-0.37%)

04 Dec, 2024 20:18

SIP TrendupStart SIP in GUFICBIO

Start SIP

Performance

  • Low
  • ₹440
  • High
  • ₹460
  • 52 Week Low
  • ₹278
  • 52 Week High
  • ₹504
  • Open Price₹454
  • Previous Close₹447
  • Volume166,039

Investment Returns

  • Over 1 Month + 1.22%
  • Over 3 Month + 13.07%
  • Over 6 Month + 41.41%
  • Over 1 Year + 36.97%
SIP Lightning

Smart Investing Starts Here Start SIP with Gufic BioSciences for Steady Growth!

Invest Now

Gufic BioSciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 52.6
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 4,463
  • P/B Ratio
  • 8.4
  • Average True Range
  • 21.77
  • EPS
  • 8.47
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.13
  • RSI
  • 56.36
  • MFI
  • 55.78

Gufic BioSciences Financials

Gufic BioSciences Technicals

EMA & SMA

Current Price
₹445.10
-1.65 (-0.37%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹428.15
  • 50 Day
  • ₹420.76
  • 100 Day
  • ₹401.55
  • 200 Day
  • ₹371.28

Resistance and Support

448.15 Pivot Speed
  • R3 477.15
  • R2 468.50
  • R1 456.80
  • S1 436.45
  • S2 427.80
  • S3 416.10

What's your outlook on Gufic BioSciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Gufic Biosciences Ltd. is a leading Indian biopharmaceutical company specializing in the development and manufacturing of high-quality pharmaceuticals, including injectables, oncology products, and active pharmaceutical ingredients (APIs). The company focuses on innovation, quality, and patient care in its offerings.

Gufic Biosciences has an operating revenue of Rs. 803.76 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 14% is healthy, ROE of 16% is good. The company has a reasonable debt to equity of 29%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 14% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 43 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Gufic BioSciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-29 Audited Results & Final Dividend
2024-02-14 Quarterly Results
2023-11-09 Quarterly Results

Gufic BioSciences F&O

Gufic BioSciences Shareholding Pattern

72.51%
2.51%
0.23%
16.01%
8.74%

About Gufic BioSciences

  • NSE Symbol
  • GUFICBIO
  • BSE Symbol
  • 509079
  • Chairman & Managing Director
  • Mr. Jayesh P Choksi
  • ISIN
  • INE742B01025

Similar Stocks to Gufic BioSciences

Gufic BioSciences FAQs

Gufic BioSciences share price is ₹445 As on 04 December, 2024 | 20:04

The Market Cap of Gufic BioSciences is ₹4463.4 Cr As on 04 December, 2024 | 20:04

The P/E ratio of Gufic BioSciences is 52.6 As on 04 December, 2024 | 20:04

The PB ratio of Gufic BioSciences is 8.4 As on 04 December, 2024 | 20:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23